Breast Cancer Network Australia (BCNA) celebrates a significant milestone in the fight against breast cancer as six commonly prescribed drugs receive approval for 60-day prescribing. This revolutionary move not only streamlines treatment but also offers substantial financial relief to patients battling this formidable disease.
The newly approved drugs encompass a range of hormone blocking therapies, including letrozole, anastrozole, and tamoxifen, among others. These medications, which collectively accounted for nearly one million prescriptions in the 2023 calendar year, play a crucial role in managing hormone receptor positive breast cancer, a subtype representing two-thirds of all breast cancer cases.
Vicki Durston, Breast Cancer Network Australia (BCNA)’s Director of Policy, Advocacy & Support Services, emphasizes the profound impact of this policy change on patients’ financial well-being. By enabling 60-day prescriptions, patients stand to save hundreds of dollars, particularly significant for therapies required over extended periods post-treatment.
Jodi Steel, a Breast Cancer Network Australia (BCNA) Consumer Representative and breast cancer survivor, attests to the tangible benefits of 60-day prescribing. Having relied on hormone blocking therapies for seven years, Steel acknowledges the substantial cost reduction afforded by the new policy. For patients like Steel, whose treatment spans years to mitigate cancer recurrence, this financial relief is invaluable.
Beyond the immediate financial relief, 60-day prescriptions offer ancillary benefits, such as reducing the frequency of doctor visits and minimizing time spent refilling prescriptions. These seemingly small conveniences significantly alleviate the burden on patients, fostering a more manageable treatment journey.
Russell Truck Driver Hit With 80 Charges After School Bus Crash Injures Dozens
The financial burden associated with breast cancer treatment is not to be understated. BCNA’s 2017 report on the financial impacts of breast cancer revealed average out-of-pocket costs exceeding $5,000, with some individuals facing expenses upwards of $21,000. These figures, which exclude additional expenses like lost income and un-subsidized treatments, underscore the pressing need for cost-saving measures.
BCNA’s advocacy efforts have played a pivotal role in championing 60-day prescribing, aligning with organizations like the Royal Australian College of General Practitioners to push for policy reform. This collaborative approach reflects a commitment to addressing financial toxicity and promoting equitable access to breast cancer care.
In light of Australia’s ongoing cost-of-living crisis, the significance of reducing the financial burden on breast cancer patients cannot be overstated. For individuals already grappling with socioeconomic disparities in healthcare access, initiatives like 60-day prescribing represent a critical step towards leveling the playing field.
Looking ahead, Breast Cancer Network Australia (BCNA) remains steadfast in its mission to empower individuals affected by breast cancer, providing comprehensive support, advocacy, and resources to navigate their journey. As the landscape of breast cancer treatment evolves, Breast Cancer Network Australia (BCNA) continues to lead the charge in ensuring that all Australians receive the highest standard of care, treatment, and support.
Key Facts:
- Six commonly prescribed breast cancer drugs approved for 60-day prescribing.
- Significant cost savings for patients, particularly those requiring long-term hormone blocking therapy.
- BCNA’s advocacy efforts instrumental in driving policy reform.
- Continued commitment to promoting equitable access to breast cancer care and support.
For quotes, content, or interviews, please contact our team for coordination.
About BCNA: Breast Cancer Network Australia (BCNA) is the country’s leading breast cancer consumer organization, providing information, support, and advocacy for those affected by breast cancer. BCNA’s mission is to ensure all Australians receive the best possible care, treatment, and support throughout their breast cancer journey.
Public Release Disclaimer: The information provided herein reflects the views and opinions of the author(s) and does not necessarily represent the official stance of BCNA or its affiliates. All content is subject to editing for clarity, style, and length.